Evidence map›Paper›PMID 41208842›Full record

ArticleWorld journal of oncology2025

Successful Immunotherapy Rechallenge Without Recurrence of Hemophagocytic Lymphohistiocytosis in a Patient With Metastatic Endometrial Cancer Previously Treated With Dostarlimab.

Emilie Rollet, Sebastien Puigrenier, Abeer Najem, Benoit Desgrousilliers, Pierre Riviere

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emilie RolletMedical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
Sebastien PuigrenierNephrology and Internal Medicine Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
Abeer NajemMedical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
Benoit DesgrousilliersMedical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.
Pierre RiviereMedical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal immune hyperactivation syndrome that can be induced by immune checkpoint inhibitors (ICIs). We report a case of a 72-year-old woman with metastatic endometrial carcinoma who developed HLH after dostarlimab treatment and underwent successful immunotherapy rechallenge with pembrolizumab-lenvatinib plus prophylactic corticosteroids without HLH recurrence. Close biological monitoring ensured no relapse of HLH during rechallenge.

Indexed as

Corticosteroid prophylaxisDostarlimabEndometrial cancerHemophagocytic lymphohistiocytosisImmune checkpoint inhibitorsImmunotherapy-related adverse eventsPembrolizumabRuxolitinib

Identifiers

PMID41208842
PMCPMC12591248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.